NEW YORK CITY, NEW YORK / ACCESS Newswire / July 8, 2025 / CMG Home Loans, the retail division of well-capitalized privately held mortgage lender, CMG Financial, is pleased to announce the appointment of Area Sales Manager, David Schwartz (NMLS# 66288). With a distinguished mortgage career spanning nearly two decades, Schwartz is guaranteed to bring his years of lending experience to the homeowners of the New York City Metropolitan Area.
A seasoned mortgage industry leader, Schwartz joins CMG from The Federal Savings Bank where he spent over 16 years, advancing to Senior Vice President. There, he oversaw sales teams across diverse NYC boroughs. A New York City native, David combines a deep understanding of the region with a customer-first mentality, helping countless homeowners navigate the lending process.
“I’m excited to join CMG Home Loans to help grow and expand their footprint throughout the five boroughs and the New York area,” said Schwartz. “I’m eager to leverage the company’s innovative products to better serve clients and give more buyers the chance to become homeowners.”
“David is not only one of the top producers in NY but he is a legend in the industry helping thousands of families achieve the dream of homeownership,” added Scott Johnson, CMG Home Loans Divisional Executive. “We are excited to grow the boroughs of NY and David will be a huge asset to help us reach our goals of being the top lender in NY.”
About CMG
CMG Mortgage, Inc. (NMLS #1820) is a well-capitalized mortgage lender founded in 1993. Founder and CEO, Christopher M. George, was Chairman of the Mortgage Bankers Association in 2019. CMG makes its products and services available to the market through three distinct origination channels including retail lending, wholesale lending, and correspondent lending. CMG currently operates in all states, including District of Columbia, and holds approvals with FNMA, FHLMC, and GNMA. CMG is widely known through the mortgage lender and housing markets for responsible lending practices, industry and consumer advocacy, product innovation, and operational efficiency.
MIAMI, FL / ACCESS Newswire / July 8, 2025 / PrivateJet.com (PrivateJet.com LLC), the leading domain in private aviation, has officially launched. The platform guides users through an advanced on-demand jet charter experience that combines innovative technology with white glove customer service. Founded by a team of experienced and passionate aviators, PrivateJet.com sets a new standard in private aviation by prioritizing safety together with luxury service, customized solutions, and reliable operations.
PrivateJet.com users can access more than 6,000 aircraft spread across 240 models which connect them to over 15,000 airports worldwide.
The website features an easy-to-use on-demand booking system that generates instant flight quotes to give users maximum flexibility during their travel times. Backed by 24/7 customer support, a dedicated aviation advisor provides assistance to travelers for all their flight needs – whether for business, leisure, or complex charter missions.
“Our mission is to redefine the private jet charter experience by merging cutting-edge technology with exceptional personal service,” said Michael Loff, Director of Charter Sales at PrivateJet.com. “We don’t just move you from point A to B, we elevate every moment of your journey,” he added.
Whether for domestic or international travel, the overall goal of PrivateJet.com is to elevate jetsetter’s booking experience, every step of the way. The company enhances the on-demand charter experience to allow for flexibility, full control, and customization on each and every flight.
NEW YORK, NY AND IXTAPAN DE LA SAL, MEXICO / ACCESS Newswire / July 8, 2025 / Skip Barber Racing School (SBRS), widely regarded as the “gateway to motorsports,” has entered into a landmark agreement with the San Roman family and their investment group to develop and operate a full-service racing circuit and karting center in the renowned resort town of Ixtapan de la Sal, Mexico.
This visionary initiative marks the debut of SBRS’s first-ever Racing Resort-a destination blending high-performance racing instruction, luxury accommodations, and immersive motorsport experiences. The development will be nestled within Gran Reserva, a storied estate known for its world-famous hot springs, championship golf course, and award-winning spa that has hosted global icons from Ava Gardner to Johnny Weissmuller.
“We are thrilled to partner with the San Roman family in what we believe is Latin America’s epicenter for motorsports,” said Michael Berg, CFO of SBRS. “This site will allow us to serve drivers and sponsors from across Mexico, Latin America, and the globe. Its close proximity to Toluca (30 minutes) and Mexico City International Airport (1.5 hours) makes it a uniquely accessible destination.”
Chairman Ricardo San Roman added, “Our resort has long been a retreat for global celebrities. With Skip Barber Racing School as our partner, we now create an entirely new destination category-a luxury motorsports hub. There is simply nothing like it.”
This expansion represents both a brand milestone and a cultural inflection point, meeting a surging regional appetite for elite motorsports experiences. The Ixtapan Racing Resort will serve as a hub where premium automotive brands, professional drivers, and motorsports enthusiasts converge.
Vince Caruso, CEO of New to The Street and Accel Media International, commented:
“As a longtime partner to the Skip Barber Racing School and with our extensive outdoor and national TV media footprint, this opens enormous opportunities to promote experiential motorsports globally. This is the beginning of something extraordinary.”
New to The Street is a globally syndicated media powerhouse broadcasting on Fox Business and Bloomberg-with a dominant outdoor media presence and a thriving digital audience. Their YouTube channel, @NewtotheStreetTV, now boasts how recently? approximately 2.9 million subscribers instagram.com+9youtube.com+9instagram.com+9-a testament to their expansive digital influence.
About Skip Barber Racing School: Founded in 1975, Skip Barber Racing School is the world’s largest automotive education and entertainment company. It conducts driving and racing schools, defensive driving programs, and high-performance experiences across the most iconic racetracks in North America.
About New to The Street: New to The Street is a globally syndicated media platform broadcasting on Fox Business, Bloomberg, and leading digital channels. With over 2.9 million YouTube subscribers, expansive social media, and iconic NYC outdoor billboards, it provides unmatched visibility for growth-stage and blue-chip brands across all sectors.
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / July 8, 2025 / CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (“CoTec” or the “Company”) is pleased to note that Mkango Resources Ltd. (AIM/TSX-V:MKA) (“Mkango”) and HyProMag Limited (“HyProMag”) have announced first production runs of recycled rare earth alloy from the commercial-scale Hydrogen Processing of Magnet Scrap (“HPMS”) vessel at Tyseley Energy Park (“TEP”) in Birmingham, UK.
This marks the first commercial-scale production of recycled neodymium-iron-boron (NdFeB) alloy using HPMS technology and represents a significant milestone for all stakeholders involved. The TEP plant is the UK’s only sintered rare earth magnet manufacturing facility and is a major step forward for both domestic and global rare earth supply chains.
Julian Treger, Chief Executive Officer of CoTec, commented: “We are delighted to see Mkango and HyProMag achieving this significant milestone, and we extend our congratulations to all involved, including the teams at the University of Birmingham and Tyseley Energy Park. This first production of recycled rare earth alloy is a critical step in validating HPMS technology at scale and sends a powerful signal for what is to come in the United States. The successful start-up at Tyseley bodes very well for our HyProMag USA joint venture, as we continue advancing detailed engineering and move toward building a secure, domestic rare earth magnet supply chain in North America.”
HyProMag USA is a 50:50 joint venture between CoTec and HyProMag (a 100% subsidiary of Maginito Limited, which is 79.4% owned by Mkango and 20.6% by CoTec). The joint venture is currently developing its first integrated rare earth magnet recycling and manufacturing facility in the Dallas-Fort Worth region, targeting commissioning in 2027.
About CoTec
CoTec Holdings Corp. is a publicly traded investment issuer listed on the TSX Venture Exchange and OTCQB under the symbols CTH and CTHCF, respectively. CoTec is a forward-thinking resource extraction company committed to transforming the global metals and minerals industry through environmentally sustainable technologies and strategic asset acquisitions.
With a mission to drive the sector toward a low-carbon future, CoTec employs a dual approach:
Investing in disruptive mineral extraction technologies that enhance efficiency and sustainability, and
Applying these technologies to undervalued mining assets to unlock their full potential.
By focusing on recycling, waste mining, and scalable solutions, the Company accelerates the production of critical minerals, shortens development timelines, and reduces environmental impact. CoTec’s model enables low capital requirements, rapid revenue generation, and high barriers to entry – positioning it as a leading mid-tier disruptor in the commodities sector.
Statements in this press release regarding the Company and its investments that are not historical facts are “forward-looking statements” that involve risks and uncertainties, including statements relating to the expected development and outcomes of first production runs by HyProMag Limited and its potential impact on the HyProMag USA project and other current or potential investments. Since forward-looking statements address future events and conditions, by their nature they involve inherent risks and uncertainties. Actual results could differ materially due to known and unknown risks and uncertainties affecting the Company, including but not limited to: resource and reserve risks; environmental risks and costs; labor costs and shortages; supply and price fluctuations in materials; increases in energy costs; contractor and subcontractor performance; project delays and cost overruns; extreme weather; and geopolitical or social disruptions.
For further details, refer to “Risk Factors” in the Company’s filing statement dated April 6, 2022, available under the Company’s profile at www.sedarplus.ca. The Company assumes no responsibility to update forward-looking statements, except as required by law. Readers are cautioned not to place undue reliance on forward-looking statements and are encouraged to consult the Company’s continuous disclosure documents.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
The CE Shop provides the tips needed for real estate business owners, brokerages, and leaders to thrive throughout the rest of 2025 and beyond
DENVER, CO / ACCESS Newswire / July 8, 2025 / A newly released quick-reference guide breaks down the most important national housing trends of the year so far-providing agents and brokers with timely, data-driven insights to stay ahead in a shifting market. Plus, it’s a FREE guide-good news for anyone needing encouragement to make the right decisions for industry success or help with business decision-making.
Key takeaways include:
Median list prices, home values, and mortgage rate trends
Inventory levels, time on market, and evolving buyer behavior
Price reductions and ongoing affordability opportunities
The CE Shop already helps over 4,000 business partners, serving over 600,000 real estate education courses taken annually. From their leadership position as educators for all four professions serving the real estate industry-real estate agents, home inspection, mortgage loan origination, and property appraisal-The CE Shop has their ear to the ground of market opportunities and partner needs.
The CE Shop is the leading provider of real estate education with online mortgage, real estate, home inspection, appraisal, and professional development courses available throughout the United States. The CE Shop produces quality education for professionals across the nation, whether they’re veterans in their industry or looking to launch a new career. We believe the right education can truly make a difference. Visit TheCEShop.com to learn more.
Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications
SAN FRANCISCO, CA / ACCESS Newswire / July 8, 2025 /
Jaguar Health, Inc.
(NASDAQ:JAGX)
(“Jaguar”) today announced that an access and benefit sharing agreement focused on two cultivated species of the coca plant –
Erythroxylum coca
and
Erythroxylum novogranatense
– from Peru has been signed between Peru’s
National Institute of Agrarian Innovation
(INIA) and Psilo Scientific, a subsidiary of
Filament Health Corp.
(OTC:FLHLF)
(“Filament”). The access agreement authorizes the research program of
Magdalena Biosciences
(“Magdalena”), a US-based joint venture formed by Jaguar and Filament, into a variety of potential mental health and central nervous system (CNS) indications for coca.
“Psilo Scientific, Filament, Jaguar and Magdalena are very pleased about the signing of this coca access agreement,” said Steven King, Ph.D., Jaguar’s Chief Sustainable Supply and Ethnobotanical Research Officer and an Advisor to Magdalena. “As part of the authorization of this research project, an
Internationally Recognized Certificate of Compliance
(IRCC) has been granted and published on the
Convention on Biological Diversity
(CBD) website. The CBD is an international treaty for the conservation of biodiversity, the sustainable use of the components of biodiversity, and the equitable sharing of the benefits derived from the use of genetic resources. An IRCC is a key mechanism under the CBD and the Nagoya Protocol to ensure fair and equitable sharing of benefits from the use of genetic resources and indigenous knowledge.”
“The entire Magdalena team is deeply grateful to our Peruvian partner organizations in this research program, the Univeridad Nacional Agraria La Molina (La Molina) and the Empresa Nacional de La Coca (ENACO) for their collaboration, expertise and guidance,” said Dr. King. “We are also grateful to the people of the Andean region who have domesticated the sacred plant, ‘mama coca’, which is and has been interwoven in the ritual, spiritual and traditional medicine of indigenous and non-indigenous communities for centuries. A great deal of the history and current work on coca was presented by indigenous leaders, scientists, government officials, social scientists and nonprofit public health experts in Peru at the
Wisdom of the Leaf Coca Summit
, organized by the
McKenna Academy
, in February 2025.”
Magdalena’s mission is to develop novel, safe, efficacious next-generation psychoactive FDA-approved plant-based drugs under FDA Botanical Guidance for mental health and CNS indications.
“We believe that the development of Botanical Drugs from ‘whole extract’ coca leaf can provide therapeutic benefit, and that the development process will benefit the people of Peru, who have been sustainably producing coca leaves for several thousand years,” said Dr. Karen Brunke, Jaguar’s EVP of Corporate and Business Development and Acting CEO of Magdalena. “In traditional medicine, coca leaves are utilized as a remedy for a wide variety of conditions, ranging from alleviating oral pain, digestive maladies, hunger, and altitude sickness, as well as muscular and skeletal aches. Many commonly used neuropsychiatric medications have side effects such as personality changes or sedation. With centuries of use by indigenous healers and traditional psychiatrists, plant-derived medicines offer potential new mechanisms of action for treating mental disorders while being potentially safer than chemically synthesized small molecule drugs that may have ‘off target’ effects.”
“The authorization from INIA to Magdalena and Psilo Scientific is a key step in the important work of exploring coca leaf’s therapeutic potential for the treatment of various mental health and CNS indications,” said Benjamin Lightburn, Chief Executive Officer of Filament Health and Magdalena Board Member.
ABOUT MAGDALENA BIOSCIENCES
Jaguar Health, Inc.
and
Filament Health Corp.
formed Magdalena Biosciences, Inc. as a joint venture in 2023 to develop novel, natural prescription medicines derived from plants for mental health and CNS indications. Boulder, Colorado-based
One Small Planet
, founded by Will Peterffy, has committed to funding of US$1,000,000. The goal of the collaboration is to extend the botanical drug development capabilities of Jaguar and Filament in order to develop pharmaceutical-grade, standardized drug candidates for mental health disorders.
ABOUT FILAMENT HEALTH (OTC:FLHLF)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with what we believe to be the first-ever natural psychedelic drug candidates.
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi
®
for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s
Entheogen Therapeutics Initiative
(ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the belief that the development of Botanical Drugs from ‘whole extract’ coca leaf can provide therapeutic benefit, and that the development process will benefit the people of Peru. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNess
Company evaluating systemic recombinant human DNase I (DNase I) in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors
FRAMINGHAM, MA / ACCESS Newswire / July 8, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. (PeriNess), has informed the Company that Bnei Zion Medical Center has commenced patient dosing in an exploratory clinical study of systemic DNase I in combination with FOLFIRINOX for the first line treatment of unresectable, locally advanced or metastatic pancreatic cancer.
Dr. Abed Agbabrya, head of Oncology at the Bnei Zion Hospital, will act as the principal investigator and all work will be conducted at The Fund for Medical Research, Development of Infrastructure and Health services – Bnei Zion Medical Center in Israel.
Dr. Dmitry Genkin, Xenetic Chairman stated, “We are very pleased with the update provided by PeriNess and for the start of patient dosing in this exploratory study. We remain committed to advancing our systemic recombinant human DNase I technology into the clinical stage. The ability of DNase I to degrade neutrophil extracellular traps (NETs) in the pancreatic cancer tumor microenvironment holds promise to improve clinical responses in a critically underserved patient population. We look forward to further exploring the full potential of DNase I.”
PeriNess has informed the Company that the exploratory study is evaluating the safety, biomarker response, pharmacokinetics (PK) and clinical activity of DNase I in combination with first line regimen of FOLFIRINOX chemotherapy in patients with locally advanced or metastatic pancreatic cancer. All patients will receive intravenous infusions of DNase I on Days 1 and 8 of consecutive 14-day cycles. Safety will be continuously evaluated until the end of the study. DNase I pharmacokinetics will be evaluated on Days 1 and 2 of the first FOLFIRINOX cycle and Days 1 and 2 of the third FOLFIRINOX cycle. Neutrophil extracellular traps biomarkers will be evaluated on Day 1 of the first FOLFIRINOX cycle and every 4 weeks thereafter. Clinical activity will be evaluated by the Objective Response Rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Progression-Free Survival (PFS).
As previously announced, in December 2024, Xenetic entered into a Clinical Trial Services Agreement with PeriNess, under which PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator initiated studies of recombinant DNase as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company’s DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase I program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “remain,” “focus”, “confidence in”, “potential”, “look forward”, “holds”, and other words of similar meaning, including, but not limited to, all statements regarding expectations with respect to the investigator initiated exploratory study being conducted by Bnei Zion Medical Center evaluating the safety, biomarker response, PK and clinical activity of DNase I in combination with first line regimen of FOLFIRINOX chemotherapy in patients with locally advanced or metastatic pancreatic cancer, including the first patient dosing under the exploratory study; all statements regarding expectations with respect to our collaboration with PeriNess; and all statements regarding expectations for our DNase I-based oncology platform, including statements regarding: DNase holding promise to improve clinical responses in a critically underserved patient population, our expectations regarding exploring the full potential of DNase I, our focus on advancing innovative immune-oncology technologies addressing difficult to treat cancers, the DNase I technology improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers, and our focus on advancing our systemic DNase I program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) the relevance of, or our ability to utilize, the data from the investigator initiated exploratory study, if any, (2)) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements, including the Clinical Trial Services Agreement with PeriNess; (3) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (4) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (5) failure to realize the anticipated potential of the DNase technologies; (6) the ability of the Company to obtain funding and implement its business strategy; and (7) other risk factors as detailed from time to time in the Company’s reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues and geopolitical events, such as the conflicts in the Ukraine and Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
Contact: JTC Team, LLC Jenene Thomas (908) 824-0775 xbio@jtcir.com
Nuclear power is increasingly seen as the next-generation source to support the energy demands of computing and AI infrastructure while boosting energy independence and decarbonizing at scale – and nuclear needs storage
bGen™ installed in Italy with Enel – a major European utility company – is an application that can serve as a strong foundation for the continued development of Brenmiller’s thermal energy storage system for integration with nuclear SMRs
Potential for major safety improvements – bGen™ system architecture supports passive heat absorption, load following, and decay heat removal
ROSH HA‘AYIN, IL / ACCESS Newswire / July 8, 2025 / Brenmiller Energy Ltd. (Nasdaq:BNRG), a leading global provider of Thermal Energy Storage (“TES”) solutions for industrial and utility customers, announced today it is developing a new version of its bGen™ TES platform technology specifically for nuclear small modular reactors (“SMRs”).
SMRs produce up to 300 MW(e) of power, significantly smaller than traditional nuclear power plants, and are designed with modular components, offering greater flexibility and potentially lower costs. While reliable for baseload generation, SMRs lack the flexibility to meet dynamic grid demands – precisely the gap that bGen™ is designed to fill.
“The global shift toward electrification and clean heat requires not only innovation but also adaptability,” said Avi Brenmiller, Chairman and Chief Executive Officer at Brenmiller Energy. “We believe that our bGen™ system, already validated in real-world grid and industrial settings, is naturally suited to support SMR decarbonization with minimal modifications.”
Enel Project as Proof of Scalability & Resilience
Brenmiller’s bGen™ system has already been installed in Italy with Enel – a major European utility company – as part of a pilot project to decarbonize combined heat and power (“CHP”) operations. This project can serve as a strong development base for future TES units tailored for SMR.
Photo: Brenmiller Energy, Enel project, Santa Barbara, Italy
Development Platform for Future SMR Integration
Unlike conventional nuclear storage integrations, Brenmiller’s solution provides a solid foundation that can be adapted and further developed to meet SMR requirements.
bGen™’s inherent heat exchanger and high thermal mass are already optimized for interfacing with secondary or tertiary loops in nuclear systems
System architecture supports passive heat absorption, load following, and decay heat removal
These attributes pave the way for potential rapid deployment in SMR-linked projects
New Product Launch Coming Soon
Brenmiller will soon introduce a bGen™ configuration tailored for SMR and high-resilience industrial applications. This next-generation product retains Brenmiller’s signature flexibility, safety, and cost-effectiveness – while unlocking powerful new use cases in the nuclear and heavy industry domains.
Governments and Industry Driving Demand
New executive orders from the U.S. Administration have fast-tracked SMRs and aim to significantly reform the U.S. nuclear industry
A $900 million U.S. Department of Energy solicitation for SMRs was issued to support American energy and artificial intelligence (“AI”) dominance
The World Bank recently reversed its prior ban on funding nuclear power and announced it will accelerate the approval of SMRs
Several countries in Europe are reembracing nuclear power as a means of boosting energy independence and decarbonizing at scale, including Denmark, which is rethinking its 40-year nuclear ban, according to a report by CNBC in May 2025
About bGen™
bGen™ ZERO is Brenmiller’s TES system, which converts electricity into heat to power sustainable industrial processes at a price that is competitive with natural gas. The bGen™ ZERO charges by capturing low-cost electricity from renewables or the grid and stores it in crushed rocks. It then discharges steam, hot water, or hot air on demand according to customer requirements. The bGen™ ZERO also supports the development of utility-scale renewables by providing critical flexibility and grid-balancing capabilities. bGen™ ZERO was named among TIME’s Best Inventions of 2023 in the Green Energy category and won Gold in the Energy Storage and Management category at the 2025 Edison Awards.
About Brenmiller Energy Ltd.
Brenmiller Energy helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller’s patented bGen™ ZERO thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers’ needs. The most experienced thermal battery developer on the market, Brenmiller operates the world’s only gigafactory for thermal battery production and is trusted by leading multinational energy companies. For more information visit the Company’s website at https://bren-energy.com/ and follow the company on X and LinkedIn.
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements when discussing: the development of the new version of the Company’s bGen™ TES platform specifically for use with SMRs; that the bGen™ system is positioned to support SMR decarbonization with minimal modifications; that the bGen™ system has the potential for major safety improvements as its architecture supports passive heat absorption, load following, and decay heat removal; the timing in which the Company will introduce a bGen™ configuration tailored for SMR and high-resilience industrial applications; that the new product will retain the Company’s flexibility, safety, and cost-effectiveness while enabling new use cases in nuclear and heavy industry; that there will be rapid deployment of the Company’s bGen™ system in SMR-linked projects due to its compatibility with nuclear systems; that global trends, including executive orders and funding initiatives, are expected to drive demand for SMR-compatible technologies like bGen™; and that policy changes by the U.S. government and international institutions will accelerate the adoption of SMRs, potentially expanding market opportunities for the Company. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company’s results include, but are not limited to: the Company’s planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 4, 2025, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
AUSTIN, TEXAS / ACCESS Newswire / July 8, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) (“Monogram” or the “Company”), an AI-driven robotics company revolutionizing orthopedic surgery, today announced the mandatory conversion of all outstanding shares of 8.00% Series D Convertible Cumulative Preferred Stock (the “Series D Preferred Stock”) that were issued in connection with the Company’s offering that closed on October 1, 2024 (the “Offering”). During the Offering, the Company issued and sold units, with each unit consisting of (a) one share of the Company’s Series D Preferred Stock and (b) one common stock purchase warrant to purchase one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”).
On July 7, 2025, the Company sent a notice of mandatory conversion to all holders of Series D Preferred Stock notifying such holders that, in accordance with Section 6(a) of the Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”) of the Series D Preferred Stock, the closing price of the Common Stock closed at or above $2.8125 per share for ten (10) consecutive trading days ending and including July 7, 2025, thereby triggering a Mandatory Conversion (as defined in the Certificate of Designation) pursuant to Section 6(a) of the Certificate of Designation. Such conversion shall be effective as of July 14, 2025.
About Monogram Technologies Inc.
Monogram Technologies (NASDAQ:MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics.
Monograms mBôs™ precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced, better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored.
Monogram has obtained FDA 510(k) clearance for its mBôs TKA System and FDA clearance for its mPress implants. The Company is required to obtain FDA clearance before it can market its products.
The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Forward-looking statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors, including those described in the Company’s filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.
Investor Relations
Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 MGRM@mzgroup.us
Cooperation expected to drive targeted awareness and ecommerce sales to the brand through LQR House’s proprietary marketing channels
MIAMI BEACH, FLORIDA / ACCESS Newswire / July 8, 2025 / LQR House Inc. (the “Company” or “LQR House”) (NASDAQ:YHC), a niche ecommerce platform specializing in the spirits and beverage industry, today announced it has signed a marketing agreement with Montauk Distilling Co. to promote its cinnamon-flavored rum.
Under the agreement, LQR House will develop and execute a tailored three-months promotional marketing campaign designed to drive brand awareness and increase online sales through its own marketplace, CWSpirits.com. The campaign will leverage LQR House’s proprietary digital tools, targeted advertising strategies, and extensive influencer network.
“Montauk Cinnamon Rum is a bold and innovative product, and exactly the kind of brand we look to support,” said Sean Dollinger, CEO of LQR House. “Our marketing division continues to grow by cooperating with founders who are passionate about what they’re building. Becoming an extension of our clients’ marketing teams to tell that story and generate results is what we do best. We believe that such highly specialized service that we offer is really hard to find elsewhere in the online spirits space.”
Montauk Distilling Co.’s cinnamon rum stands out for its unique flavor profile and strong consumer appeal, aligning perfectly with LQR House’s focus on differentiated, high-quality beverage brands.
This cooperation represents another step in LQR House’s ongoing mission to support emerging and craft spirits brands with targeted, data-driven marketing that directly connects products with customers.
About LQR House Inc.
LQR House intends to become a prominent force in the wine and spirits e-commerce sector, epitomized by its flagship alcohol marketplace, cwspirits.com. This platform seamlessly delivers a diverse range of emerging, premium, and luxury spirits, wines, and champagnes from esteemed retail partners like Country Wine & Spirits. Functioning as a technology-driven hub, LQR House utilizes software, data analytics, and artificial intelligence to elevate consumer experience. CWSpirits.com stands out as the go-to destination for modern, convenience-oriented shoppers, providing a curated selection of alcohol products delivered to homes across the United States. Beyond its role in an e-commerce sector, LQR House is a marketing agency with a specialized focus on the alcohol industry. The Company measures campaign success by directly correlating it with sales on CWSpirits.com, demonstrating a return on investment. Backed by an influential network of around 460 figures in the alcohol space, LQR House strategically drives traffic to CWSpirits.com, enhancing brand visibility. LQR House intends to disrupt the traditional landscape of the alcohol industry, driven by its dedication to providing an unparalleled online purchasing experience and delivering tailored marketing solutions.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Shareholders can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. Forward-looking statements contained in this press release are made only as of the date of this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in other reports and documents that the Company files from time to time with the United States Securities and Exchange Commission (the “SEC”). You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the headings “Risk Factors”. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in other reports and documents that the Company files from time to time with the SEC. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. References and links to websites have been provided as a convenience, and the information contained on such websites has not been incorporated by reference into this press release.
